Yasa Gul Mutlu
Overview
Explore the profile of Yasa Gul Mutlu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yigit Kaya S, Melek E, Mutlu Y, Bekoz H, Maral S, Kaynar L, et al.
Ann Hematol
. 2025 Feb;
PMID: 40016397
No abstract available.
2.
Yigit Kaya S, Mutlu Y, Yucel O, Nizam Ozen I, Atas U, Melek E, et al.
Indian J Hematol Blood Transfus
. 2025 Feb;
41(1):38-42.
PMID: 39917490
This study investigates the efficacy and safety of generic plerixafor (Pleksor - Gen Pharma) compared to the original plerixafor (Mozobil - Sanofi) in patients with multiple myeloma undergoing ASCT. A...
3.
Askin A, Bektas S, Serin I, Mutlu Y, Aydin B, Sevindik O
Indian J Hematol Blood Transfus
. 2024 Jul;
40(3):527-530.
PMID: 39011240
No abstract available.
4.
Yigit Kaya S, Mutlu Y, Malkan U, Mehtap O, Keklik Karadag F, Korkmaz G, et al.
Leuk Res
. 2024 Apr;
140:107495.
PMID: 38599153
Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies....
5.
Mutlu Y, Yigit Kaya S, Maral S, Melek E, Baslar Z, Kaynar L, et al.
Front Immunol
. 2023 Oct;
14:1276295.
PMID: 37901215
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific...
6.
Erol V, Mutlu Y, Balik B, Mert A, Mergen S, Mergen M, et al.
J Dtsch Dermatol Ges
. 2023 Sep;
21(9):1025-1028.
PMID: 37700402
No abstract available.
7.
Serin I, Sevindik O, Aydin B, Melek E, Mutlu Y, Bilgen H, et al.
Transfus Apher Sci
. 2023 Sep;
62(6):103809.
PMID: 37690861
Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and...
8.
Mutlu Y, Aydin B, Cakir A, Canoz O, Erol C, Sevindik O
Eurasian J Med
. 2023 Jul;
55(2):114-119.
PMID: 37403909
Objective: Surgical excisional biopsy is accepted as the standard of care approach in the diagnosis of lympho- mas. Financial issues related to the increased cost and the invasive nature of...
9.
Erol V, Mutlu Y, Balik B, Mert A, Mergen S, Mergen M, et al.
J Dtsch Dermatol Ges
. 2023 Jul;
21(9):1025-1027.
PMID: 37401140
No abstract available.
10.
Yigit Kaya S, Bektas S, Askin A, Aydin B, Mutlu Y, Sevindik O
Ann Hematol
. 2023 Apr;
102(6):1599-1600.
PMID: 37099080
No abstract available.